← All Fennec Pharmaceuticals INC filings

Fennec Pharmaceuticals INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
FENC
Fennec Pharmaceuticals INC
10-K: Fennec Pharmaceuticals Reports Record 2025 PEDMARK Sales, Eliminates Debt
Fennec Pharmaceuticals announced record net product sales of $44.6 million for fiscal year 2025, a 50% increase year-over-year, alongside the full redemption of its outstanding debt.
NASDAQ
FENC
Fennec Pharmaceuticals INC
10-K: Fennec Pharmaceuticals Reports FY2024 Results: PEDMARK Sales Surge, Debt Reduced, and European Expansion Underway
Fennec Pharmaceuticals reports a 40% increase in PEDMARK net product sales for FY2024, alongside strategic debt reduction and expansion into European markets.
NASDAQ
FENC
Fennec Pharmaceuticals INC
10-K: Fennec Pharmaceuticals Reports Strong 2023 Results and Secures European Licensing Deal
Fennec Pharmaceuticals announced positive full-year 2023 financial results, highlighted by $21.3 million in PEDMARK net product sales and a significant licensing agreement for European commercialization.